Spinogenix, Inc., a clinical-stage biopharmaceutical company, has published peer-reviewed preclinical research in the journal Experimental Eye Research demonstrating the neuroprotective effects of their investigational drug SPG302 in a mouse model of glaucoma. The study provides early proof of concept that synaptic regeneration may represent a novel therapeutic strategy to protect retinal neurons and preserve vision in glaucoma, a leading cause of irreversible blindness worldwide.
Study Findings Demonstrate Neuroprotection in Glaucoma Model
Glaucoma affects approximately 80 million people globally and leads to vision loss primarily through damage to retinal ganglion cells (RGCs) and their axons, which transmit visual signals from the eye to the brain. Current treatment focuses on lowering intraocular pressure (IOP), the main modifiable risk factor; however, many patients experience disease progression even with controlled IOP, indicating additional mechanisms contribute to optic nerve damage.
The new study evaluated daily oral administration of SPG302 for eight weeks in mice with induced elevated IOP, mimicking glaucoma. Results showed significant preservation of RGC survival and axon integrity accompanied by maintained retinal function measured by electroretinography, a translational method used clinically to assess retinal activity. Importantly, the drug protected retinal synapses, indicated by normalized synaptic protein markers, suggesting synaptic regeneration underlies its neuroprotective effect. These results underscore synapse loss as an early and critical event in glaucoma damage and support targeting synaptic preservation to halt or reverse disease progression.
Expert Commentary and Therapeutic Implications
Dr. Robert N. Weinreb, a glaucoma expert at the University of California, San Diego, remarked that the findings are encouraging as they illuminate the possibility of protecting retinal ganglion cells by reversing synaptic loss with a clinical-stage compound. This approach marks a shift from solely managing IOP to directly targeting neuronal and synaptic health. Dr. Weinreb expressed optimism that SPG302 could offer a new neuroprotective option not only for glaucoma but also for other retinal neurodegenerative diseases.
Spinogenix CEO Dr. Stella Sarraf highlighted the study’s validation of retinal synapse loss as a pivotal step in glaucoma and discussed plans to advance SPG302 into clinical trials aimed at glaucoma and potentially other retinal conditions characterized by synaptopathy.
About SPG302 and Its Broader Neurodegenerative Potential
SPG302 is an oral, once-daily drug designed to regenerate glutamatergic synapses—the essential communication points between neurons—thereby restoring neural network function. This synaptic regenerative mechanism is novel and considered first-in-class among treatments for neurodegenerative and neuropsychiatric conditions. Beyond glaucoma, SPG302 is under investigation in Phase 2 clinical trials for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and schizophrenia, conditions where synaptic loss contributes to cognitive and motor decline.
The drug’s potential to reverse synaptic degeneration and improve cognitive, respiratory, and motor functions marks a paradigm shift in the development of neuroprotective therapies. Regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, have granted Orphan Drug and Fast Track designations for SPG302 in various indications, reflecting its innovativeness and unmet medical need.
Glaucoma: A Leading Cause of Vision Loss with Unmet Treatment Needs
Glaucoma remains the leading cause of irreversible blindness worldwide, and current therapies primarily aim to slow progression by lowering IOP. However, not all glaucoma patients exhibit elevated IOP, and many continue losing vision despite treatment, highlighting the necessity for treatments addressing the underlying neurodegeneration. As synapse loss on retinal ganglion cells precedes overt neuron death and vision loss, targeting synaptic health could preserve vision earlier in the disease course.
Currently, no therapies exist that directly repair synaptic connections in glaucoma. The preclinical evidence for SPG302’s synaptic regenerative and neuroprotective effects offers a promising new therapeutic avenue that could transform glaucoma management and benefit millions of patients worldwide.
Implications for Public Health and Future Research
This advancement matters because glaucoma causes substantial global health burden due to irreversible vision loss, which impacts quality of life and independence. Developing neuroprotective treatments that preserve or restore retinal neurons and synapses can reduce blindness incidence and increase years of healthy vision. The study emphasizes the importance of expanding beyond pressure-lowering therapies to address the complex mechanisms of retinal neurodegeneration.
Moving forward, clinical trials will be critical to confirm the safety and efficacy of SPG302 in human glaucoma patients. Success could herald a new class of synaptic regenerative therapies for ocular and central nervous system diseases, shifting paradigms in disease-modifying treatment strategies.
For more on cutting-edge medical breakthroughs and neurodegenerative research, see Globally Pulse Health. Additional expert insights on glaucoma treatment innovations are available from the World Health Organization and the National Eye Institute.
